Advertisement
Skip to Content
Morningstar

Cronos Group Inc CRON Stock Quote

Morningstar Rating
| Rating as of

XTSE: CRON

Last close prices updated as of Jun 05, 2023, 1:50 PM EST | CAD
  • Last Close 2.37
  • Sector Healthcare
  • Industry Drug Manufacturers - Specialty & Generic
  • Investment Style Small Blend
  • Day Range 2.26  –  2.35
  • Year Range 2.26  –  4.88
  • Market Cap 866.3562 Mil
  • Volume / Avg 60,525.0 /  227,548.3
  • Price / Sales 7.60
  • Price / Book 0.59
  • Forward Div Yield —
  • Trailing Div Yield —

Morningstar‘s Stock Analysis CRON

Valuation
Currency in —
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Cronos Earnings: Overhead Cost Cuts Are Helping, but Growth Concerns Keep Profitability Away

Analyst Note

| Kristoffer Inton |

No-moat Cronos reported first-quarter 2023 results, highlighted by slow top line growth and continued losses. Revenue declined 20% to $20 million, made worse by the currency effect of a stronger U.S. dollar. Adjusted EBITDA losses narrowed $2 million to $17 million. Although the company made better progress than we expected on overhead costs, sluggish sales growth and gross margins that have been slower to recover than we expected weigh on our forecast. We’ve cut our fair value estimates to $3 and CAD 4 per share, down from $4 and CAD 5.50, respectively.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CRON

More

Company Profile CRON

Business Description

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland, Germany, and Israel, with the latter being a market of particular strength. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

Contact
111 Peter Street, Suite 300
Toronto, ON, M5V 2H1, CAN
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Employees 447

Related Articles CRON

Stock Analyst Update

Cronos Earnings: Overhead Cost Cuts Are Helping, but Growth Concerns Keep Profitability Away

Kristoffer Inton
Stock Analyst Update

Cronos Shows Respectable Progress on Narrowing Losses

However, positive EBITDA remains years away.
Kristoffer Inton
Stock Analyst Update

Which Stocks Will Benefit from Cannabis' Landslide Win?

Every ballot measure was approved.
Kristoffer Inton
Stock Strategist Industry Reports

Covering Cannabis

We see some values, although we don’t think any of the companies have moats.
Kristoffer Inton

Related News CRON

More

Competitors & Peers CRON

More on CRON’s Competitors & Peers

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of CRON’s competitive advantage.

Cronos Group Inc

XTSE: CRON

Aurora Cannabis Inc

XTSE: ACB

Canopy Growth Corp

XTSE: WEED

Tilray Brands Inc

XNAS: TLRY
Price
2.280.681.061.67
Currency
CADCADCADUSD
Change
−$0.10 (4.01%) −$0.03 (4.23%) −$0.08 (7.02%) −$0.05 (2.91%)
Market Cap
866.36 Mil231.87 Mil552.26 Mil1.09 Bil
Industry
Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Healthcare
Healthcare
Healthcare

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Cronos Group Inc Stock

No. CRON does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

CRON’s market cap is 866.36 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

CRON’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

CRON’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare CRON’s historical performance against its industry peers and the overall market.